#6 – Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials
6-Once-Daily-Oral-Sarecycline
#7 – Lebrikizumab, a High Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis
7-Lebrikizumab-High-Affinity
#8 – Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Primary Axillary Hyperhidrosis
8-Limited-Systemic-Exposure
#9 – Maintenance of Response with up to 4 Years of Continuous Guselkumab Treatment: Results from the VOYAGE 1 Phase 3 Trial
9-Maintenence-of-Response